Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists probe immune clues to boost cancer therapy success

NCT ID NCT07180992

Summary

This study aims to understand why some patients with multiple myeloma respond better to CAR-T cell therapy than others. Researchers will analyze a specific type of immune cell, called a monocyte, in about 25 patients before and after they receive CAR-T treatment. The goal is to find markers that can predict treatment success and help improve future care.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHRU Amiens

    RECRUITING

    Amiens, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.